Gadolinium and spinal cord lesions were consistently predictive.
Several studies have questioned the long-term significance of gadolinium-enhancing (GdE) and spinal cord (SC) lesions in early MS (NEJM JW Neurol Jun 2018 and Mult Scler 2018; 24:481). To further examine the associations, investigators analyzed 164 patients with clinically isolated syndrome.
Mean follow-up was 15 years. MS developed in 119 (73%): relapsing-remitting (RR) in 94 and secondary-progressive (SP) in 25. Development of SPMS was associated with ≥1 spinal cord lesion at baseline, ≥2 GdE lesions at baseline or follow-up at year 3, increasing supratentorial T2 lesions at years 1 and 3, and new infratentorial lesions at years 1 and 3. Logistic modeling confirmed that ≥2 baseline enhancing lesions and ≥1 baseline spinal cord lesions were…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)